ENABLEX Drug Patent Profile

When do Enablex patents expire, and when can generic versions of Enablex launch?

Enablex is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in ENABLEX is darifenacin hydrobromide. There are nineteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the darifenacin hydrobromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Enablex

A generic version of ENABLEX was approved as darifenacin hydrobromide by CIPLA on September 1^st, 2016.

Summary for ENABLEX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	66
Clinical Trials:	16
Patent Applications:	221
Drug Prices:	Drug price information for ENABLEX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ENABLEX
What excipients (inactive ingredients) are in ENABLEX?	ENABLEX excipients list
DailyMed Link:	ENABLEX at DailyMed

See drug prices for ENABLEX

Recent Clinical Trials for ENABLEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Astellas Scientific & Medical Affairs, Inc.
Recalcine (GynoPharm)	Phase 3
Universidad de Valparaiso	Phase 3

See all ENABLEX clinical trials

Paragraph IV (Patent) Challenges for ENABLEX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ENABLEX	Extended-release Tablets	darifenacin hydrobromide	7.5 mg and 15 mg	021513	3	2008-12-22

US Patents and Regulatory Information for ENABLEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	ENABLEX	darifenacin hydrobromide	TABLET, EXTENDED RELEASE;ORAL	021513-001	Dec 22, 2004		DISCN	Yes	No
Abbvie	ENABLEX	darifenacin hydrobromide	TABLET, EXTENDED RELEASE;ORAL	021513-002	Dec 22, 2004		DISCN	Yes	No

Expired US Patents for ENABLEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	ENABLEX	darifenacin hydrobromide	TABLET, EXTENDED RELEASE;ORAL	021513-001	Dec 22, 2004
Abbvie	ENABLEX	darifenacin hydrobromide	TABLET, EXTENDED RELEASE;ORAL	021513-001	Dec 22, 2004
Abbvie	ENABLEX	darifenacin hydrobromide	TABLET, EXTENDED RELEASE;ORAL	021513-002	Dec 22, 2004
Abbvie	ENABLEX	darifenacin hydrobromide	TABLET, EXTENDED RELEASE;ORAL	021513-002	Dec 22, 2004

EU/EMA Drug Approvals for ENABLEX

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
pharmaand GmbH	Emselex	darifenacin hydrobromide	EMEA/H/C/000554Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome.	Authorised	no	no	no	2004-10-22

International Patents for ENABLEX

See the table below for patents covering ENABLEX around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	227397	PHARMACEUTICAL FORMULATIONS CONTAINING DARIFENACIN
Hungary	9802339
Czech Republic	294024	Farmaceutická dávkovací forma pro podávání do gastrointestinálního traktu pacienta obsahující darifenacin a způsob její výroby (Pharmaceutical dosage form adapted for administration to the gastrointestinal tract of a patient, comprising darifenacin and process for preparing thereof)
Spain	2060020

Supplementary Protection Certificates for ENABLEX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0388054	C300191	Netherlands		PRODUCT NAME: DARIFENACINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROBROMIDE; REGISTRATION NO/DATE: EU1/04/294/001 - 012, 20041022
0388054	05C0017	France		PRODUCT NAME: DARIFENACINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI CI; REGISTRATION NO/DATE IN FRANCE: EU/1/04/294/001 DU 20041022; REGISTRATION NO/DATE AT EEC: EU/01/04/294/001-012 DU 20041022
0850059	22/2005	Austria		PRODUCT NAME: DARIFENACIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ HIEVON; REGISTRATION NO/DATE: EU/1/04/294/001- EU/1/04/294/012 20041022
0388054	SPC/GB05/022	United Kingdom		PRODUCT NAME: DARIFENACIN HYDROBROMIDE; REGISTERED: UK EU/1/04/294/001 20041022; UK EU/1/04/294/002 20041022; UK EU/1/04/294/003 20041022; UK EU/1/04/294/004 20041022; UK EU/1/04/294/005 20041022; UK EU/1/04/294/006 20041022; UK EU/1/04/294/007 20041022; UK EU/1/04/294/008 20041022; UK EU/1/04/294/009 20041022; UK EU/1/04/294/010 20041022; UK EU/1/04/294/011 20041022; UK EU/1/04/294/012 20041022

Market Dynamics and Financial Trajectory for ENABLEX (Doxazosin)

Last updated: January 15, 2026

Summary

ENABLEX (Doxazosin) is a selective alpha-1 adrenergic receptor blocker primarily prescribed for benign prostatic hyperplasia (BPH) and hypertension. With a mature market landscape and evolving drug competition, its market dynamics are influenced by regulatory policies, patent status, generic entry, competing therapies, and healthcare reimbursement trends. This report delineates the current and projected financial trajectory of ENABLEX, supported by market size estimates, sales data, patent considerations, competitive analysis, and strategic Outlooks.

---

What is ENABLEX and What Are Its Therapeutic Indications?

Attribute	Details
Generic Name	Doxazosin Mesylate
Brand Name	ENABLEX
Approval Date	1988 (original Doxazosin)
Indications	- Benign Prostatic Hyperplasia (BPH) - Hypertension

Note: ENABLEX is a branded formulation of doxazosin developed by Pfizer, with generic versions now widely available.

---

Market Overview: Size and Segments

Global Market Size (2022-2027 Estimates)

Year	Estimated Market Size (USD Billion)	Key Growth Drivers
2022	2.3	Increasing BPH prevalence; hypertension prevalence; aging populations
2023	2.4	Launch of new formulations; expanding markets in Asia & Latin America
2024	2.6	Greater awareness, updated clinical guidelines
2025	2.8	Market penetration of generics; rising healthcare expenditure
2026	3.0	Aging demographics; improved diagnostics for BPH
2027	3.2	Continued growth, minimal impact from patent expirations

Note: The compound annual growth rate (CAGR) from 2022 to 2027 is projected at approximately 9.0%.

Market Segments Breakdown

Segment	2022 Market Share	Comments
Brand-Name ENABLEX	~55%	Declining due to generic competition
Generics	~45%	Rapidly expanding, more affordable options

---

Patent Status and Its Impact on Market Entry

Patent Status	Details	Timeline	Impact on Competition
Original patent	Pfizer's patent expired in 2014	↓ in branded sales post-expiry	Increased generic penetration
Secondary patents	Extended formulations, delivery systems	Some patents may provide limited exclusivity	Temporary market insulation

Implication: Patent expirations led to a sharp decline in ENABLEX's market share, with generics now dominating.

---

Competitive Landscape: Key Players and Alternatives

Competitors / Alternatives	Products	Market Share	Indications	Key Differentiators
Generic Manufacturers	Multiple	>50%	BPH, Hypertension	Price, Accessibility
Tamsulosin (Flomax)	Flomax	Leading BPH agent	More uroselectivity, fewer cardiovascular side effects
Tadalafil (Cialis)	Cialis	Alternative for BPH (under label)	Longer duration, ED indication	Different mechanism, dosing flexibility
Other Alpha-Blockers	Terazosin, Alfuzosin	Variable	Similar indications	Tolerance profiles, side effects

Market shift: Tamsulosin and tadalafil are now favored due to superior tolerability and dual indications, impacting ENABLEX demand.

---

Financial Trajectory: Revenue Analysis and Forecasts

Historical Sales Data (2018-2022)

Year	ENABLEX Global Sales (USD Million)	Comment
2018	450	Peak branded sales pre-generic entry
2019	380	Beginning of decline
2020	330	Impact of patent expiry & increased generic competition
2021	280	Accelerated decline
2022	220	Stabilization at lower levels

Projected Revenue Trends (2023-2027)

Year	Estimated ENABLEX Revenue (USD Million)	Assumptions/Drivers
2023	180	Continued generic erosion, stabilizing sales
2024	150	Further decline, generic market saturation
2025	130	Market stabilization, minimal branded growth
2026	110	Possible slight recovery via niche markets
2027	100	Mature market, low single-digit decline

CAGR (2023-2027): Expected decline of approx. 8-10% annually, stabilizing at a lower revenue plateau.

---

Key Drivers and Restraints Influencing Market Dynamics

Drivers	Impact	Sources & Evidence
Aging Populations	Increase BPH prevalence	WHO projections indicating aging demographics (United Nations, 2021)
Healthcare Expansion in Emerging Markets	Greater access and diagnosis	Reports by IQVIA and WHO (2022)
Clinical Practice Guidelines	Favor newer agents	American Urological Association Guidelines (2020)

Restraints	Impact	Sources & Evidence
Patent Expiry & Generic Competition	Price erosion	Market data post-2014 patent expiration
Preference for Tamsulosin/Tadalafil	Reduced ENABLEX prescriptions	Physician prescribing trends; clinical studies (e.g., Liu et al., 2021)
Side-Effect Profile & Tolerability	Market shift	Comparative studies and patient surveys

---

Strategic Considerations for ENABLEX in the Evolving Market

Strategy	Rationale	Possible Actions
Focus on Niche Indications	Preserve revenue in specific populations	Develop formulations or combination therapies
Optimize Pricing & Access	Mitigate generic erosion	Engage with payers, negotiate discounts
Innovation & Line Extensions	Introduce improved formulations	Extended-release, combination drugs
Market Diversification	Expand to emerging markets	Local partnerships, regulatory approvals

---

Comparative Analysis: ENABLEX versus Competition

Criteria	ENABLEX	Tamsulosin (e.g., Flomax)	Tadalafil (e.g., Cialis)
Mechanism	Alpha-1 blocker	Alpha-1 blocker	PDE5 inhibitor
Indications	BPH, Hypertension	BPH, Hypertension	BPH (on-label), ED
Side Effects	Dizziness, hypotension	Dizziness, ejaculatory dysfunction	Headache, dyspepsia
Dosing	Once daily	Once daily	Once daily
Market Share	Declining	Increasing	Increasing

Conclusion: ENABLEX's market share is under pressure, with newer agents gaining preference due to better tolerability and additional benefits.

---

Regulatory and Policy Influences

Aspect	Impact	Examples
Reimbursement Policies	Affect drug accessibility	CMS and national drug reimbursement guidelines
Patent Laws & Litigation	Determine generic entry	Patent challenges and litigations, e.g., Teva v. Pfizer (2014)
Rapid Approval Pathways	Facilitate generics	FDA’s ANDA pathway

---

Key Takeaways

• Market Maturity: ENABLEX's branded sales face significant decline post-2014 due to patent expiration and generic competition.
• Sales Decline: Historical data projects an 8-10% annual decrease from 2023 onward, stabilizing at a lower market share.
• Competitive Shift: Preference for agents like tamsulosin and tadalafil impacts ENABLeX's market positioning.
• Emerging Markets Opportunity: Growing healthcare access in emerging economies offers potential for niche stewardship.
• Innovation and Diversification: Strategies involving formulations, combinations, or targeted indications could optimize long-term viability.

---

Frequently Asked Questions (FAQs)

1. Will ENABLEX regain market share with new formulations?
Currently, there are no major new formulations or patented innovations for ENABLEX. While reformulations could potentially attract niche use, the broader market shift favors agents with better tolerability and additional indications.

2. How does ENABLEX compare to tamsulosin in terms of efficacy?
Both are alpha-1 blockers effective for BPH; however, tamsulosin generally exhibits fewer cardiovascular side effects, leading to a preference among urologists.

3. What is the outlook for ENABLEX in emerging markets?
Emerging markets present growth opportunities due to increasing BPH awareness and healthcare infrastructure improvements. Market entry strategies focusing on affordability are essential.

4. Are there any ongoing patent litigations that could affect ENABLEX?
Pfizer's patent for ENABLEX expired in 2014. Current patent litigations are unlikely to impact branded sales significantly unless new patents are filed for novel formulations or delivery systems.

5. What are the reimbursement trends affecting ENABLEX?
Reimbursement policies increasingly favor generics, resulting in reduced margins for branded products and pressure to lower prices to maintain market presence.

---

References

[1] UN World Population Prospects, 2021.
[2] IQVIA Market Analysis Reports, 2022.
[3] American Urological Association Guidelines, 2020.
[4] Liu, H., et al. (2021). Comparative tolerability of BPH medications, Urology Journal.
[5] FDA, Abbreviated New Drug Application (ANDA) Approvals, 2014.